<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:58:20Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10692230" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10692230</identifier>
        <datestamp>2023-12-03</datestamp>
        <setSpec>tp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
              <journal-title-group>
                <journal-title>Translational Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2158-3188</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10692230</article-id>
              <article-id pub-id-type="pmcid">PMC10692230</article-id>
              <article-id pub-id-type="pmc-uid">10692230</article-id>
              <article-id pub-id-type="pmid">38040678</article-id>
              <article-id pub-id-type="pmid">38040678</article-id>
              <article-id pub-id-type="publisher-id">2674</article-id>
              <article-id pub-id-type="doi">10.1038/s41398-023-02674-1</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1297-6548</contrib-id>
                  <name>
                    <surname>Alexander</surname>
                    <given-names>Laith</given-names>
                  </name>
                  <address>
                    <email>laith.alexander@kcl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2256-1648</contrib-id>
                  <name>
                    <surname>Hawkins</surname>
                    <given-names>Peter C. T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Evans</surname>
                    <given-names>Jennifer W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1152-5323</contrib-id>
                  <name>
                    <surname>Mehta</surname>
                    <given-names>Mitul A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zarate</surname>
                    <given-names>Carlos A.</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220mzb33</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution>Institute of Psychiatry, Psychology and Neuroscience, </institution><institution>King’s College London &amp; Centre for Neuroimaging Sciences, King’s College London, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04xeg9z08</institution-id><institution-id institution-id-type="GRID">grid.416868.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0464 0574</institution-id><institution>Experimental Therapeutics and Pathophysiology Branch, </institution><institution>National Institute of Mental Health, </institution></institution-wrap>Bethesda, MD USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <elocation-id>371</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>11</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>11</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Activity changes within the anterior cingulate cortex (ACC) are implicated in the antidepressant effects of ketamine, but the ACC is cytoarchitectonically and functionally heterogeneous and ketamine’s effects may be subregion specific. In the context of a double-blind randomized placebo-controlled crossover trial investigating the clinical and resting-state fMRI effects of intravenous ketamine <italic>vs.</italic> placebo in patients with treatment resistant depression (TRD) <italic>vs.</italic> healthy volunteers (HV), we used seed-based resting-state functional connectivity (rsFC) analyses to determine differential changes in subgenual ACC (sgACC), perigenual ACC (pgACC) and dorsal ACC (dACC) rsFC two days post-infusion. Across cingulate subregions, ketamine differentially modulated rsFC to the right insula and anterior ventromedial prefrontal cortex, compared to placebo, in TRD <italic>vs.</italic> HV; changes to pgACC-insula connectivity correlated with improvements in depression scores. Post-hoc analysis of each cingulate subregion separately revealed differential modulation of sgACC-hippocampal, sgACC-vmPFC, pgACC-posterior cingulate, and dACC-supramarginal gyrus connectivity. By comparing rsFC changes following ketamine <italic>vs.</italic> placebo in the TRD group alone, we found that sgACC rsFC was most substantially modulated by ketamine <italic>vs.</italic> placebo. Changes to sgACC-pgACC, sgACC-ventral striatal, and sgACC-dACC connectivity correlated with improvements in anhedonia symptoms. This preliminary evidence suggests that accurate segmentation of the ACC is needed to understand the precise effects of ketamine’s antidepressant and anti-anhedonic action.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Depression</kwd>
                <kwd>Clinical pharmacology</kwd>
                <kwd>Neuroscience</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000272</institution-id>
                      <institution>DH | National Institute for Health Research (NIHR)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>ACF-2022-17-016</award-id>
                  <award-id>CRF-2016-10023</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Alexander</surname>
                      <given-names>Laith</given-names>
                    </name>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>Mitul A.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000265</institution-id>
                      <institution>RCUK | Medical Research Council (MRC)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/R005885/1</award-id>
                  <award-id>MR/S003444/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>Mitul A.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000025</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>ZIAMH002857</award-id>
                  <award-id>NCT00088699</award-id>
                  <award-id>04-M-0222</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>Carlos A.</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Nature Limited 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par2">Ketamine is a rapidly acting antidepressant drug, with promising effects in patients with treatment-resistant depression (TRD). Ketamine is also effective in ameliorating anhedonia, which can otherwise be refractory to conventional antidepressant treatment [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. Both preclinical and clinical evidence suggests that modulation of anterior cingulate cortex (ACC) activity is important in ketamine’s antidepressant and anti-anhedonic effects (as reviewed in [<xref ref-type="bibr" rid="CR4">4</xref>]).</p>
              <p id="Par3">The ACC is heterogenous and is comprised of several subregions including the subgenual (sgACC), perigenual (pgACC), and dorsal (dACC) regions – each of which has different anatomical [<xref ref-type="bibr" rid="CR5">5</xref>] and functional [<xref ref-type="bibr" rid="CR6">6</xref>] connectivity. Distinctions have been drawn, for example, between a dorsal dACC-parietal attention network and a ventral pg/sgACC-default mode affective network, suggesting different functions across a small anatomical extent [<xref ref-type="bibr" rid="CR6">6</xref>]. It is therefore likely that different ACC subregions likely undergo differential modulation following ketamine administration, and these subregions may contribute differently to ketamine’s therapeutic action.</p>
              <p id="Par4">It remains unclear which subregions are important in ketamine’s antidepressant effects. Rodent studies suggest that the rodent homolog of sgACC (specifically Brodmann Area [BA]25) – infralimbic cortex (IL) – is a critical site of action mediating ketamine’s acute antidepressant-like effects [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>], and the rodent homolog of pgACC – prelimbic cortex (PL) – mediates sustained effects [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. In humans, whilst several neuroimaging studies suggest that ketamine-induced changes in ACC activity or connectivity can correlate with antidepressant effects [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>], the locus of change varies cross the extent of the ACC [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par5">Furthermore, whether certain subregions are more or less important in ketamine’s anti-anhedonic effects is uncertain. Preclinical work in marmosets – whose ACC is more homologous to human ACC – suggests that ketamine’s modulation of sgACC and a downstream reward-related network (including dACC, insula, and ventral striatum) is critical in ameliorating reward-related deficits induced by sgACC over-activity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In humans, work has implicated changes throughout the ACC. In patients with bipolar disorder and in patients with MDD, anti-anhedonic effects of ketamine correlate with increased <sup>18</sup>F-FDG uptake in dACC [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Ketamine has also been shown to modulate pgACC-striatal connectivity differentially in TRD compared to healthy volunteers, correlating with improvements in anhedonia symptoms [<xref ref-type="bibr" rid="CR19">19</xref>]. Finally, ketamine reduces sgACC hyperactivity to positive incentives on a monetary incentive delay task, again correlating with improvements in anhedonia [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
              <p id="Par6">In light of this growing body of preclinical and clinical work, circuit-based perspectives on ketamine’s action have emerged, with the ACC as a region of importance [<xref ref-type="bibr" rid="CR4">4</xref>]. Particular interest has focused on impaired top-down regulation of sgACC by ‘higher’ cortical regions such as dorsolateral PFC (BA9/46), frontopolar/anterior ventromedial prefrontal cortex (vmPFC; BA10m), and pgACC (BA32) [<xref ref-type="bibr" rid="CR21">21</xref>]. Comprehensive tract tracing work in macaques shows these regions are intimately connected [<xref ref-type="bibr" rid="CR22">22</xref>]. Top-down regulation of sgACC can be disrupted by chronic stress [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], and successful antidepressant treatment across a variety of modalities may be associated with restoration of top-down inhibition of sgACC by higher prefrontal regions [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p>
              <p id="Par7">The modulation of different ACC subregions by ketamine has not been compared in a single study. In the context of a double-blind, randomized placebo-controlled trial, we compared the modulation of sgACC, pgACC and dACC resting-state functional connectivity (rsFC) with the rest of the brain, following ketamine <italic>vs.</italic> placebo, in patients with treatment-resistant depression (TRD) <italic>vs.</italic> healthy volunteers (HV). We additionally investigated how these changes correlated with ketamine’s antidepressant and anti-anhedonic effects. We hypothesized that ketamine would differentially modulate rsFC across sgACC, pgACC, and dACC, and that modulations of ACC rsFC may be relevant to the therapeutic effects of ketamine. Our hypotheses were not pre-registered and were carried out as a post-hoc analysis of a pre-existing dataset (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00088699">NCT00088699</ext-link>).</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par8">The methods in this paper are similar to those described previously [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p>
              <sec id="Sec3">
                <title>Participants</title>
                <p id="Par9">Data for 50 participants (21 HV and 29 TRD) were taken from a randomized-clinical trial (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00088699">NCT00088699</ext-link>), with inclusion and exclusion criteria previously published [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. TRD patients were diagnosed with a current major depressive episode without psychotic features, had not responded to at least one adequate antidepressant trial during their current episode (mean ± SD number of failed lifetime trials: 6 ± 3), and had a Montgomery-Åsberg Depression Rating Scale (MADRS [<xref ref-type="bibr" rid="CR28">28</xref>]) score of 20 or more at screening and before each infusion. Before scanning, all TRD patients were medication-free for at least two weeks (three weeks for aripiprazole, 5 weeks for fluoxetine). HVs had no Axis I disorder.</p>
                <p id="Par10">Information regarding participant characteristics can be found in Table <xref rid="Tab1" ref-type="table">1</xref> and in <xref rid="MOESM1" ref-type="media">Supplementary Methods</xref> (Participant Information). All participants provided written informed consent, and the study was approved by the NIH IRB.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participant demographic and clinical characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Healthy volunteers (HV)</th><th>Treatment-resistant depression (TRD)</th></tr></thead><tbody><tr><td>Total number in sample</td><td>21 (13 female, 8 male)</td><td>29 (18 female, 11 male)</td></tr><tr><td>Age in years</td><td>35 (±11)</td><td>36 (±10)</td></tr><tr><td>BMI in kg/m<sup>2</sup></td><td>27.8 (±4.6)</td><td>26.4 (±5.7)</td></tr><tr><td>Length of illness</td><td/><td>21 (±11) years</td></tr><tr><td>Length of current episode</td><td/><td>45 (±73) months</td></tr><tr><td>Number of failed treatments</td><td/><td>6 (±3) adequate trials</td></tr><tr><td>Baseline MADRS score</td><td>1 (±2)</td><td>33 (±5)</td></tr><tr><td>Baseline SHAPS score</td><td>18 (±4)</td><td>40 (±4)</td></tr><tr><td>Baseline TEPS-anticipatory score</td><td>47 (±6)</td><td>23 (±8)</td></tr><tr><td>Baseline TEPS-consummatory score</td><td>40 (±5)</td><td>23 (±5)</td></tr><tr><td>Figs. <xref rid="Fig1" ref-type="fig">1</xref>–<xref rid="Fig3" ref-type="fig">3</xref> &amp; <xref rid="Fig4" ref-type="fig">4</xref>A: Number of post-ketamine fMRI images</td><td>20 (12 female, 8 male)</td><td>26 (16 female, 10 male)</td></tr><tr><td>Figs. <xref rid="Fig1" ref-type="fig">1</xref>–<xref rid="Fig3" ref-type="fig">3</xref> &amp; <xref rid="Fig4" ref-type="fig">4</xref>A: Number of post-placebo fMRI images</td><td>17 (11 female, 6 male)</td><td>25 (13 female, 12 male)</td></tr><tr><td>Fig. <xref rid="Fig4" ref-type="fig">4</xref>B, C: Number of subjects with both fMRI and SHAPS/TEPS data, both post-ketamine and post-placebo</td><td/><td>11 (5 female, 6 male)</td></tr><tr><td>Fig. <xref rid="Fig5" ref-type="fig">5</xref>A, B: Number of subjects with fMRI and SHAPS data post-ketamine</td><td/><td>15 (9 female, 6 male)</td></tr><tr><td>Fig. <xref rid="Fig5" ref-type="fig">5A</xref>: Number of subjects with fMRI and SHAPS data post-placebo</td><td/><td>12 (6 female, 6 male)</td></tr></tbody></table><table-wrap-foot><p>(± standard deviation, where relevant).</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec4">
                <title>Study procedures</title>
                <p id="Par11">Resting-state (rs)fMRI imaging was carried out in the context of a double-blind randomized placebo-controlled crossover study. Participants were randomized to receive either a single intravenous infusion of ketamine hydrochloride (0.5 mg/kg over 40 min) or placebo (0.9% saline solution) during the first session, and the converse treatment during the second session two weeks later. rsfMRI scans were obtained 2 days after each infusion. MADRS, Snaith–Hamilton Pleasure Scale (SHAPS [<xref ref-type="bibr" rid="CR29">29</xref>]), and Temporal Experience of Pleasure Scale (TEPS) anticipatory and consummatory [<xref ref-type="bibr" rid="CR30">30</xref>] ratings were acquired 60 min before each infusion and at 40, 80, 120, 230 min, and 1, 2, 3, 7, 10, and 11 days following each infusion. SHAPS and TEPS were used as measures of anhedonia. Two-day timepoints are analyzed here.</p>
                <p id="Par12">The primary objective was to compare the seed-to-whole brain rsFC changes of sgACC, pgACC, and dACC with ketamine <italic>vs.</italic> placebo, in TRD <italic>vs.</italic> HV. Secondary objectives were the analysis of seed-to-whole brain rsFC changes comparing ketamine <italic>vs.</italic> placebo in the TRD group alone, and to test whether rsFC changes correlated with ketamine’s antidepressant or anti-anhedonic effects.</p>
              </sec>
              <sec id="Sec5">
                <title>fMRI acquisition and pre-processing</title>
                <p id="Par13">Data acquisition and pre-processing were identical to those described in [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Briefly, eight-minute rsfMRI scans (3.5 × 3.5 × 3.5 mm resolution, 64 × 64 matrix, repetition time [TR] of 2.5 s) were acquired on a 3T GE Healthcare MRI scanner (HDx; Milwaukee, WI) with an eight-channel coil. Subjects were instructed to close their eyes, relax, and remain awake. Cardiac and respiration traces were also recorded using the manufacturer’s photo-plethysmograph and respiratory belt, respectively. Pre-processing steps included de-spiking, slice-timing correction, physiological noise correction, motion alignment, blurring to 6 mm full-width-at-half-maximum, motion censoring, bandpass filtering (0.01–0.1 Hz) followed by alignment with the Montreal Neurological Institute (MNI) 152 standard space. Data points were censored if there was more than an estimated 0.2 mm of motion (Euclidean norm) per TR, and the data set was excluded from further analysis if there were more than 15 censored time points.</p>
              </sec>
              <sec id="Sec6">
                <title>Seed regions</title>
                <p id="Par14">ACC seeds were chosen based on a previous study identifying changes in subregional ACC structure and function associated with rumination in depression [<xref ref-type="bibr" rid="CR31">31</xref>]. Left and right seeds were combined for analysis to increase signal-to-noise, as we predicted left and right seeds would show similar activity. The bilateral ACC seeds consisted of two 5 mm radius spheres and corresponded to caudal sgACC (BA24/25; MNI coordinates in RAI format: ±12 −27 −12), pgACC (BA24/32; ±6 −34 −5), and dACC (BA8/32; ±6 −28 41; Fig. <xref rid="Fig1" ref-type="fig">1A</xref>). Despite their proximity (particularly of sgACC and pgACC), the ROIs filled non-overlapping voxels, and showed substantial differences in rsFC (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). The ROIs were in regions of adequate signal (and are shown overlayed on an example EPI in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Regions of interest (ROIs) and resting-state functional connectivity (rsFC) patterns.</title><p><bold>A</bold> Bilateral ROI seeds for sgACC (left), pgACC (center) and dACC (right). <bold>B</bold> Top left shows the main effect of region in the overall statistical model, with smaller images showing contrasts between sgACC and pgACC (top right), pgACC and dACC (bottom left), and sgACC and dACC (bottom right). Warm clusters indicate higher rsFC to the former region, and cool clusters indicate higher rsFC to the latter region. Despite ROI proximity (particularly of sgACC and pgACC), there are substantial differences in rsFC to the rest of the brain.</p></caption><graphic xlink:href="41398_2023_2674_Fig1_HTML" id="d32e586"/></fig></p>
              </sec>
              <sec id="Sec7">
                <title>Data analysis</title>
                <p id="Par15">Seed-to-whole-brain rsFC analyses were performed using AFNI (v 22.3.07) [<xref ref-type="bibr" rid="CR32">32</xref>]. Due to exclusion of some scans for excess motion, the final post-ketamine sample included 26 TRD participants and 20 HVs, and the final post-placebo sample included 25 TRD participants and 17 HVs. Similar to the methodology described in [<xref ref-type="bibr" rid="CR19">19</xref>], rsFC Fisher-transformed Z maps were generated at the single-subject level using 3dNetCorr [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
                <p id="Par16">Linear-mixed effects models (3dLMEr [<xref ref-type="bibr" rid="CR34">34</xref>]) were used at the group-level to determine the effects of group, treatment and region on rsFC. The model took the form: group × treatment × region + order + (1|subject) + (1|subject:treatment) + (1|subject:region), where:<list list-type="bullet"><list-item><p id="Par17">group is a between-subject factor with two levels (TRD, HV);</p></list-item><list-item><p id="Par18">treatment is a within-subject factor with two levels (ketamine, placebo);</p></list-item><list-item><p id="Par19">region is a within-subject factor with three levels (sgACC, pgACC, dACC);</p></list-item><list-item><p id="Par20">group × treatment × region is the interaction between these three factors;</p></list-item><list-item><p id="Par21">order is a between-subject factor with two levels (subject’s infusion order; ketamine first or second); and</p></list-item><list-item><p id="Par22">(1|subject), (1|subject:treatment) and (1|subject:region) are a random effects within subjects.</p></list-item></list></p>
                <p id="Par23">Results of the main interaction effect (group × treatment × region) are reported as a chi-square (χ<sup>2</sup>) statistic with two degrees of freedom, as per the output of AFNI’s 3dLMEr. Post-hoc general linear <italic>t</italic>-style tests were specified to explore:<list list-type="bullet"><list-item><p id="Par24">region-specific group × treatment interactions separately for sgACC, pgACC and dACC;</p></list-item><list-item><p id="Par25">region-specific effects of treatment within the TRD group alone;</p></list-item><list-item><p id="Par26">effects of region alone, to demonstrate expected patterns of seed-whole brain rsFC; and</p></list-item><list-item><p id="Par27">group × order interaction to explore the possibility of differential expectancy and carry-over effects between the groups.</p></list-item></list></p>
                <p id="Par28">A cluster-forming threshold of <italic>p</italic> &lt; 0.001 (uncorrected) with cluster-level family-wise error (FWE) correction at α &lt; 0.05 was used to correct for multiple comparisons. Monte-Carlo simulation in AFNI (3dFWHMx and 3dClustSim) estimated a minimum cluster size of 24 voxels.</p>
                <p id="Par29">To correlate changes in connectivity with changes in symptom scores, significant clusters for the main group × treatment × region interaction, and clusters for the effect of treatment within the TRD group alone, were correlated with changes in MADRS, SHAPS and TEPS-anticipatory/TEPS-consummatory scores. Differences (ketamine – placebo) in MADRS, SHAPS and TEPS-anticipatory/TEPS-consummatory scores at day two post-infusion were correlated with changes in rsFC (ketamine – placebo) at day two post-infusion. Pearson correlation coefficients were calculated, and statistical significance was assessed at <italic>p</italic> &lt; 0.05, two-tailed. Notably, SHAPS and TEPS scores were only measured in a subset of patients (<italic>n</italic> = 11), which reduced the sample size available for these correlations (as reported in Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
                <p id="Par30">Post-hoc correlation of significant clusters with symptom improvements has associated bias as described in ref. [<xref ref-type="bibr" rid="CR35">35</xref>]; namely, the ROIs used to correlate with symptom improvements were identified in a group/condition analysis, and we analyzed the same ROIs to explore correlations with a factor that distinguishes between groups. This bias also includes ROI definition, which can include some selective noise, particularly at the periphery. Therefore, we also carried out whole-brain regressions with clinical symptom changes, which have reduced power but are not biased. To do this, we first determined whether any brain regions were differentially associated with MADRS or SHAPS scores post-ketamine <italic>vs.</italic> post-placebo in the TRD group, using AFNI’s 3dLMEr with the model: treatment × [MADRS/SHAPS] + order + (1|subject), where treatment is a within-subject factor with two levels (ketamine, placebo) and MADRS/SHAPS is a within-subject continuous variable.</p>
                <p id="Par31">Post-hoc general linear <italic>t</italic>-style tests were carried out to explore regions whose post-ketamine connectivity to the ROI was correlated with post-ketamine MADRS or SHAPS scores. To control for post-placebo connectivity, we incorporated this as a voxelwise covariate in AFNI’s 3dMVM. The model took the form [MADRS/SHAPS] + placebo_scan, where the placebo_scan was a voxelwise covariate reflecting connectivity changes under placebo, and the effect of MADRS/SHAPS is the effect of interest.</p>
                <p id="Par32">No a priori power analysis was performed because the present study was a secondary analysis of a clinical trial [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
              </sec>
            </sec>
            <sec id="Sec8" sec-type="results">
              <title>Results</title>
              <p id="Par33">Participant demographic and clinical characteristics are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. The significant rsFC clusters identified in the neuroimaging analyses are presented Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cluster sizes, center of mass coordinates and test statistic values of regions identified in the analyses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Effect</th><th>Seed</th><th>Label</th><th>Size (voxels)</th><th>Peak <italic>x</italic></th><th>Peak <italic>y</italic></th><th>Peak <italic>z</italic></th><th>Statistic</th></tr></thead><tbody><tr><td rowspan="2">Group × treatment × region interaction (Fig. <xref rid="Fig2" ref-type="fig">2</xref>)</td><td rowspan="2">All</td><td>Right insula</td><td>28</td><td>−58.0</td><td>+9.0</td><td>+11.0</td><td><italic>χ</italic><sup>2</sup> = 18.1</td></tr><tr><td>Anterior vmPFC</td><td>42</td><td>+0.0</td><td>−53.0</td><td>−11.0</td><td><italic>χ</italic><sup>2</sup> = 18.0</td></tr><tr><td>Main effect of group</td><td>All</td><td colspan="6">Nil</td></tr><tr><td>Main effect of treatment</td><td>All</td><td colspan="6">Nil</td></tr><tr><td>Main effect of region</td><td>All</td><td colspan="6">See Fig. <xref rid="Fig1" ref-type="fig">1B</xref></td></tr><tr><td>Main effect of order</td><td>All</td><td colspan="6">Nil</td></tr><tr><td>Group × order interaction</td><td>All</td><td colspan="6">Nil</td></tr><tr><td rowspan="5">Group × treatment interaction (Fig. <xref rid="Fig3" ref-type="fig">3</xref>)</td><td rowspan="2">sgACC (BA24/25)</td><td>Right hippocampus and parahippocampal gyrus</td><td>29</td><td>−38.0</td><td>+30.0</td><td>−14.0</td><td><italic>Z</italic> = −3.56</td></tr><tr><td>Anterior vmPFC</td><td>46</td><td>+7.0</td><td>−52.0</td><td>−12.0</td><td><italic>Z</italic> = 3.50</td></tr><tr><td rowspan="2">pgACC (BA24/32)</td><td>Dorsal posterior cingulate cortex</td><td>69</td><td>+0.0</td><td>+63.0</td><td>+40.0</td><td><italic>Z</italic> = −2.60</td></tr><tr><td>Ventral posterior cingulate cortex</td><td>33</td><td>−1.0</td><td>+37.0</td><td>+35.0</td><td><italic>Z</italic> = −2.85</td></tr><tr><td>dACC (BA8/32)</td><td>Left supramarginal gyrus</td><td>26</td><td>+56.0</td><td>+22.0</td><td>+39.0</td><td><italic>Z</italic> = 3.95</td></tr><tr><td rowspan="7">TRD, effect of treatment (Figs. <xref rid="Fig4" ref-type="fig">4</xref> and S<xref rid="MOESM1" ref-type="media">2</xref>)</td><td>All</td><td colspan="6">Nil</td></tr><tr><td rowspan="4">sgACC (BA24/25)</td><td>Right hippocampus and parahippocampal gyrus</td><td>24</td><td>−40.0</td><td>+33.0</td><td>−15.0</td><td><italic>Z</italic> = -3.07</td></tr><tr><td>pgACC (BA24/32)</td><td>32</td><td>−2.0</td><td>−36.0</td><td>+5.0</td><td><italic>Z</italic> = 2.91</td></tr><tr><td>Anterior vmPFC</td><td>61</td><td>+4.0</td><td>−53.0</td><td>−12.0</td><td><italic>Z</italic> = 3.79</td></tr><tr><td>Right ventral striatum</td><td>37</td><td>−17.0</td><td>−2.0</td><td>−4.0</td><td><italic>Z</italic> = 5.28</td></tr><tr><td>pgACC (BA24/32)</td><td colspan="6">Nil</td></tr><tr><td>dACC (BA8/32)</td><td colspan="6">Nil</td></tr><tr><td rowspan="6">HV, effect of treatment</td><td>All</td><td>Dorsal and ventral posterior cingulate cortex</td><td>45</td><td>+0.0</td><td>+46.0</td><td>+41.0</td><td><italic>Z</italic> = 3.64</td></tr><tr><td>sgACC (BA24/25)</td><td colspan="6">Nil</td></tr><tr><td rowspan="3">pgACC (BA24/32)</td><td>Ventral posterior cingulate cortex</td><td>156</td><td>−1.0</td><td>+33.0</td><td>+35.0</td><td><italic>Z</italic> = 3.87</td></tr><tr><td>Right dorsal posterior cingulate cortex</td><td>34</td><td>−11.0</td><td>+65.0</td><td>+34.0</td><td><italic>Z</italic> = 4.65</td></tr><tr><td>Left dorsal posterior cingulate cortex</td><td>35</td><td>+15.0</td><td>+63.0</td><td>+31.0</td><td><italic>Z</italic> = 4.06</td></tr><tr><td>dACC (BA8/32)</td><td colspan="6">Nil</td></tr><tr><td>TRD, Treatment × SHAPS (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>)</td><td>sgACC (BA24/25)</td><td>dACC</td><td>48</td><td>−2.0</td><td>−28.0</td><td>+35.0</td><td><italic>Z</italic> = 5.18</td></tr><tr><td>Effect of SHAPS post-ketamine, controlled for placebo (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>)</td><td>sgACC (BA24/25)</td><td>dACC</td><td>43*</td><td>−1.0</td><td>−8.0</td><td>+30.0</td><td><italic>t</italic> = 3.65</td></tr></tbody></table><table-wrap-foot><p>Coordinates are in RAI format, in MNI space. Clusters reported at <italic>α</italic> &lt; 0.05, with a cluster forming threshold of <italic>p</italic> &lt; 0.001 and an extent of 24 voxels, except *reported at a threshold of <italic>p</italic> &lt; 0.005.</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec9">
                <title>Clinical results</title>
                <p id="Par34">At day two following treatment, ketamine significantly improved MADRS scores (mean difference -6.5 [95% CI -10.6 to -2.5]; paired <italic>t</italic>-test, <italic>p</italic> = 0.003), TEPS-anticipatory scores (mean difference 6.8 [95% CI 2.9 to 9.5]; paired <italic>t</italic>-test, <italic>p</italic> = 0.038), TEPS-consummatory scores (mean difference 5.6 [95% CI 1.8 to 6.1]; paired <italic>t</italic>-test, <italic>p</italic> = 0.018) and showed a trend to improve SHAPS scores (mean difference -5.2 [95% CI -10.7 to 0.2]; paired <italic>t</italic>-test, <italic>p</italic> = 0.057) compared to placebo (Supplementary Fig. S<xref rid="MOESM1" ref-type="media">2</xref>). There was no correlation between the improvement in MADRS scores and the improvement in SHAPS (<italic>R</italic><sup>2</sup> = 0.169, <italic>p</italic> = 0.173) or TEPS-consummatory (<italic>R</italic><sup>2</sup> = 0.034, <italic>p</italic> = 0.544) scores. There was correlation between the improvement in TEPS-anticipatory and MADRS (<italic>R</italic><sup>2</sup> = 0.371, <italic>p</italic> = 0.027) scores. This suggests the depression and anhedonia scores are measuring distinct but partially overlapping constructs.</p>
              </sec>
              <sec id="Sec10">
                <title>Ketamine differentially modulates ACC subregional rsFC compared to placebo in TRD <italic>vs.</italic> HV</title>
                <p id="Par35">At day two following treatment, fMRI imaging revealed a significant group × treatment × region interaction, suggesting differential modulation by ketamine compared to placebo, in TRD <italic>vs.</italic> HV, across the three ACC subregions. Significant interaction clusters included the right insula (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>) and bilateral anterior vmPFC (BA10m; Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). Changes in rsFC between pgACC – but not sgACC or dACC – and the right insula correlated with improvements in MADRS scores (Fig. <xref rid="Fig2" ref-type="fig">2C</xref>). rsFC changes did not correlate with improvements in SHAPS scores (not shown).<fig id="Fig2"><label>Fig. 2</label><caption><title>Clusters showing a significant group × treatment × region interaction.</title><p>Images show significant clusters from a seed-based resting-state functional connectivity (rsFC) analysis, cluster thresholded at <italic>α</italic> &lt; 0.05, with a cluster forming threshold of <italic>p</italic> &lt; 0.001 and an extent of 24 voxels. Graphs show mean connectivity values (Fisher’s <italic>z</italic>-scores) between the seed and extracted cluster from whole brain analysis. HV healthy volunteers (<italic>n</italic> = 21), TRD treatment-resistant depression (<italic>n</italic> = 29), PLA placebo, KET ketamine. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, ****<italic>p</italic> &lt; 0.0001, ns not significant. <bold>A</bold> rsFC of ACC subregions to the right insula was differentially modulated by ketamine <italic>vs.</italic> placebo, in TRD <italic>vs.</italic> HV (group × treatment × region interaction, <italic>F</italic><sub>2,105</sub> = 7.40, <italic>p</italic> = 0.001). sgACC and dACC showed similar rsFC patterns to the right insula (<italic>p</italic> = 0.229) whereas sgACC <italic>vs.</italic> pgACC (<italic>p</italic> &lt; 0.0001) and dACC <italic>vs.</italic> pgACC (<italic>p</italic> = 0.001) showed differences. <bold>B</bold> rsFC of ACC subregions to the anterior ventromedial prefrontal cortex (vmPFC; BA10m) was also differentially modulated across treatment and group (group × treatment × region interaction, <italic>F</italic><sub>2,105</sub> = 4.64, <italic>p</italic> = 0.012). Here, sgACC and pgACC showed similar rsFC patterns (<italic>p</italic> = 0.636); dACC showed distinct rsFC to the anterior vmPFC compared to sgACC (<italic>p</italic> &lt; 0.0001) and pgACC (<italic>p</italic> &lt; 0.0001). <bold>C</bold> In the 20 TRD participants who had both ketamine and placebo scan data, [ketamine – placebo] changes in rsFC between pgACC and the right insula correlated with [ketamine – placebo] improvements in Montogomery-Åsberg Depression Rating Scale (MADRS) scores at day 2 post-infusion (<italic>R</italic><sup>2</sup> = 0.258, <italic>p</italic> = 0.022).</p></caption><graphic xlink:href="41398_2023_2674_Fig2_HTML" id="d32e1308"/></fig></p>
                <p id="Par36">Post-hoc general-linear <italic>t</italic>-style tests for each ACC subregion revealed significant group × treatment interactions between sgACC and the anterior vmPFC &amp; right hippocampus (Fig. <xref rid="Fig3" ref-type="fig">3A</xref>); pgACC and the posterior cingulate cortex (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>); and dACC and the supramarginal gyrus (Fig. <xref rid="Fig3" ref-type="fig">3C</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Differential effects of ketamine <italic>vs.</italic> placebo in TRD (<italic>n</italic> = 29 total) <italic>vs.</italic> HV (<italic>n</italic> = 21 total) in individual ACC subregions.</title><p>Images show significant clusters from seed-based resting-state functional connectivity (rsFC) analysis, cluster thresholded at <italic>α</italic> &lt; 0.05, with a cluster forming threshold of <italic>p</italic> &lt; 0.001 and an extent of 24 voxels. Graphs show mean rsFC values (Fisher’s z-scores) between the seed and extracted cluster from whole brain analysis. HV healthy volunteers, TRD treatment-resistant depression, PLA placebo, KET ketamine. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, ****<italic>p</italic> &lt; 0.0001, ns not significant. <bold>A</bold> sgACC-right hippocampal rsFC (treatment × group, <italic>F</italic><sub>1,35</sub> = 30.7, <italic>p</italic> &lt; 0.0001) and sgACC-anterior ventromedial prefrontal cortex (vmPFC; BA10m) rsFC (treatment × group, <italic>F</italic><sub>1,35</sub> = 20.1, <italic>p</italic> &lt; 0.001) was differentially altered by ketamine <italic>vs.</italic> placebo in TRD <italic>vs.</italic> HV. In the former case, rsFC was increased by ketamine in HV (effect of treatment: <italic>p</italic> &lt; 0.001) but decreased in TRD (<italic>p</italic> &lt; 0.001). In the latter case, rsFC was increased by ketamine in TRD (<italic>p</italic> &lt; 0.001) with a tendency to be decreased in HV (<italic>p</italic> = 0.065). <bold>B</bold> pgACC-posterior cingulate cortex rsFC was differentially altered by ketamine <italic>vs.</italic> placebo in TRD <italic>vs.</italic> HV (larger dorsal cluster: treatment × group, <italic>F</italic><sub>1,35</sub> = 5.12, <italic>p</italic> = 0.029). Whilst ketamine significantly increased rsFC in HV (effect of treatment: <italic>p</italic> = 0.013) there was no significant change in the TRD group (<italic>p</italic> = 0.994). <bold>C</bold> dACC-left supramarginal gyrus rsFC was differentially altered by ketamine <italic>vs.</italic> placebo in TRD <italic>vs.</italic> HV (treatment × group, <italic>F</italic><sub>1,35</sub> = 21.6, <italic>p</italic> &lt; 0.0001). Ketamine decreased rsFC in HV (effect of treatment: <italic>p</italic> = 0.002), but increased connectivity in TRD (<italic>p</italic> = 0.011).</p></caption><graphic xlink:href="41398_2023_2674_Fig3_HTML" id="d32e1446"/></fig></p>
              </sec>
              <sec id="Sec11">
                <title>In TRD, changes in sgACC (BA24/25) rsFC correlate with improvements in anhedonia scores</title>
                <p id="Par37">Following the identification of significant interaction effects, general linear <italic>t</italic>-style tests were carried out to explore the effect of treatment (ketamine <italic>vs.</italic> placebo) within the TRD group alone (<italic>n</italic> = 26 post-ketamine and <italic>n</italic> = 25 post-placebo) for rsFC of sgACC, pgACC and dACC ROIs separately. No significant clusters corresponding to an effect of treatment in the TRD group were found for pgACC or dACC rsFC. However, sgACC rsFC was significantly modulated by ketamine in the TRD group: connectivity was increased to bilateral pgACC, bilateral anterior vmPFC, and right ventral striatum, and decreased to right hippocampus/parahippocampal gyrus (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Modulation of sgACC (BA24/25) connectivity by ketamine <italic>vs.</italic> placebo, in patients with TRD (<italic>n</italic> = 26 post-ketamine and <italic>n</italic> = 25 post-placebo; <italic>n</italic> = 11 for symptom correlations).</title><p>Images show significant clusters from seed-based resting-state functional connectivity (rsFC) analysis, cluster-thresholded at α &lt; 0.05, with a cluster forming threshold of <italic>p</italic> &lt; 0.001 and an extent of 24 voxels. <bold>A</bold> In patients with TRD, ketamine increased sgACC-pgACC, anterior vmPFC and ventral striatal rsFC compared to placebo, but decreased sgACC-hippocampal formation rsFC. <bold>B</bold> [Ketamine – placebo] increases in rsFC between sgACC-pgACC correlated with improvements in Snaith Hamilton Pleasure Scale (SHAPS) scores (<italic>R</italic><sup>2</sup> = 0.384, <italic>p</italic> = 0.042). <bold>C</bold> [Ketamine – placebo] increases in rsFC between sgACC-ventral striatum correlated with improvements in Temporal Experience of Pleasure Scale (TEPS)-anticipatory scores (<italic>R</italic><sup>2</sup> = 0.411, <italic>p</italic> = 0.034; note that one point is obscured beneath another on the graph) but not TEPS-consummatory scores (<italic>R</italic><sup>2</sup> = 0.137, <italic>p</italic> = 0.263; not shown).</p></caption><graphic xlink:href="41398_2023_2674_Fig4_HTML" id="d32e1522"/></fig></p>
                <p id="Par38">SHAPS scores and TEPS-anticipatory/TEPS-consummatory scores, together with fMRI data for both ketamine and placebo scans, were available for a subset of TRD patients (<italic>n</italic> = 11). We correlated [ketamine – placebo] changes in SHAPS/TEPS scores with the [ketamine – placebo] changes in sgACC rsFC to the pgACC, vmPFC, striatal and hippocampal clusters identified above. For these patients, ketamine-induced increases in sgACC-pgACC rsFC correlated with improvements in SHAPS scores (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). Changes to sgACC-ventral striatal rsFC were significantly correlated with improvements in TEPS-anticipatory (<italic>R</italic><sup>2</sup> = 0.411, <italic>p</italic> = 0.034; Fig. <xref rid="Fig4" ref-type="fig">4C</xref>) and not TEPS-consummatory (<italic>R</italic><sup>2</sup> = 0.137, <italic>p</italic> = 0.263) scores (and showed a trend to correlate with improvements in SHAPS scores, <italic>R</italic><sup>2</sup> = 0.287, <italic>p</italic> = 0.082). This suggests a differential contribution of sgACC-striatal rsFC to temporally distinct types of anhedonia symptoms. Changes to sgACC-hippocampal rsFC showed a trend to correlate with improvements in SHAPS scores (<italic>R</italic><sup>2</sup> = 0.338, <italic>p</italic> = 0.061) and changes to sgACC-anterior vmPFC rsFC did not correlate. Changes in sgACC rsFC did not correlate with improvements in MADRS scores (<italic>n</italic> = 20; not shown).</p>
              </sec>
              <sec id="Sec12">
                <title>Whole-brain regressions of clinical scores with sgACC connectivity reveal correlations between sgACC-dACC rsFC and anhedonia scores</title>
                <p id="Par39">Post-hoc correlation of significant clusters with symptom improvements has associated bias (as described in “Methods” section (Data Analysis)); a regression analysis at the whole-brain level has reduced power but is unbiased. We carried out whole-brain regressions of SHAPS/MADRS scores with sgACC rsFC maps, firstly exploring whether any regions showed significantly different relationships with clinical scores following ketamine <italic>vs.</italic> placebo (treatment × score interaction). In 15 TRD patients where fMRI and SHAPS data were available post-ketamine, analysis revealed a cluster in the dACC (BA24/32, Fig. <xref rid="Fig5" ref-type="fig">5A</xref>) whose rsFC to sgACC was positively associated with post-ketamine SHAPS scores but negatively associated with post-placebo SHAPS scores. No significant regions were found associated with MADRS scores (not shown).<fig id="Fig5"><label>Fig. 5</label><caption><title>Whole-brain regressions of anhedonia symptom scores (Snaith Hamilton Pleasure Scale, SHAPS) with sgACC rsFC changes in patients with TRD (<italic>n</italic> = 15 post-ketamine and <italic>n</italic> = 12 post-placebo).</title><p>For figure <bold>A</bold>, the image shows significant clusters from seed-based resting-state functional connectivity (rsFC) analysis, cluster-thresholded at <italic>α</italic> &lt; 0.05, with a cluster forming threshold of <italic>p</italic> &lt; 0.001 and an extent of 24 voxels. For figure <bold>B</bold>, the image shows a dACC cluster with a threshold of <italic>p</italic> &lt; 0.005. Graphs show correlations between absolute SHAPS scores <italic>vs.</italic> absolute sgACC-dACC rsFC (Fisher’s z-score; either ketamine and placebo [<bold>A</bold>] or ketamine alone [<bold>B</bold>]) measured two days following infusion. <bold>A</bold> sgACC-dACC rsFC was positively associated with SHAPS scores post-ketamine (<italic>R</italic><sup>2</sup> = 0.575, <italic>p</italic> = 0.001) but was negatively associated with SHAPS scores post-placebo (<italic>R</italic><sup>2</sup> = 0.338, <italic>p</italic> = 0.048). <bold>B</bold> After controlling for rsFC changes post-placebo, a 39-voxel dACC cluster was significant at <italic>p</italic> &lt; 0.005 voxels and sgACC rsFC to this cluster was correlated with post-ketamine SHAPS scores (<italic>R</italic><sup>2</sup> = 0.484, <italic>p</italic> = 0.004).</p></caption><graphic xlink:href="41398_2023_2674_Fig5_HTML" id="d32e1649"/></fig></p>
                <p id="Par40">We additionally explored whether any clusters showed a significant association with SHAPS/MADRS scores following ketamine treatment, after controlling for connectivity changes under placebo by incorporating placebo connectivity as a voxelwise covariate. Whilst no clusters were identified at <italic>p</italic> &lt; 0.001, at a relaxed uncorrected threshold of <italic>p</italic> &lt; 0.005, we noted a single dACC cluster at <italic>p</italic> &lt; 0.005, k = 39 voxels, whose rsFC to sgACC was positively associated with post-ketamine SHAPS scores (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>). No significant regions were found associated with post-ketamine MADRS scores (not shown).</p>
              </sec>
            </sec>
            <sec id="Sec13" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par41">Here we show that subregions of the ACC undergo differential modulation by intravenous ketamine, compared to placebo, in patients with TRD <italic>vs.</italic> HV. Ketamine differentially modulates ACC subregional rsFC to the right insula and anterior vmPFC in TRD <italic>vs.</italic> HV. rsFC changes between pgACC and the insula correlated with improvements in MADRS scores, supporting suggestions that ketamine’s modulation of pgACC connectivity is important in its post-acute (in this study, day two) antidepressant effects [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
              <p id="Par42">Post-hoc examination of rsFC changes within each ACC subregion separately highlighted that rsFC of ventral ACC divisions (pgACC and sgACC) to affective and DMN regions (posterior cingulate cortex and anterior vmPFC/hippocampus respectively) was modulated. By contrast, ketamine modulated connectivity of dACC to the supramarginal gyrus, which constitutes part of the somatosensory association cortex. These differential effects are consistent with known connectivity of the ACC: ventral regions contribute to affective networks and the DMN, whereas dorsal regions contribute to frontoparietal somatosensory and attention networks [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
              <p id="Par43">In TRD patients, sgACC underwent the most substantial rsFC changes of ACC subregions in response to ketamine compared to placebo. Whilst post-hoc comparisons identified that ketamine significantly altered sgACC rsFC to pgACC, hippocampus/parahippocampal gyrus, ventral striatum, and anterior vmPFC, no significant changes were found for pgACC or dACC. We previously hypothesized that ketamine may change sgACC connectivity to nodes of the DMN [<xref ref-type="bibr" rid="CR4">4</xref>] and we found evidence to support this: ketamine decreased sgACC-hippocampal formation rsFC and increased sgACC-pgACC rsFC. Importantly, increases in sgACC-pgACC rsFC correlated with improvements in SHAPS scores, suggesting that ketamine’s anti-anhedonic effects are mediated by changes in sgACC-pgACC connectivity.</p>
              <p id="Par44">Connectivity changes between pgACC and sgACC have previously been implicated in MDD. Anatomically, these regions are densely interconnected, with pgACC/32 making excitatory contacts on sgACC/25 pyramidal cells as well as inhibitory interneurons [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Higher cortical regions such as the dorsolateral PFC and pgACC/32 are thought to provide top-down regulation of sgACC/25, and the loss of this in MDD is thought to impair adaptive coping [<xref ref-type="bibr" rid="CR21">21</xref>]. In this study, ketamine increased connectivity between pgACC and sgACC, which may reflect an amelioration of impairments in top-down regulation. Here we show this may have clinical relevance; pgACC/sgACC rsFC change correlated with improvements in SHAPS scores.</p>
              <p id="Par45">Connectivity between the ACC and the hippocampus has also been consistently implicated in depression, as these regions are particularly sensitive to the effects of chronic stress [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Hippocampal-ACC circuitry has been implicated in the antidepressant effects of ketamine. In rodents, optogenetic and pharmacogenetic activation of hippocampal-infralimbic projections replicates the sustained antidepressant effects of ketamine [<xref ref-type="bibr" rid="CR39">39</xref>]. Several human neuroimaging studies also support ketamine-induced modulations of hippocampal-prefrontal circuitry as being relevant to its antidepressant effects [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In this study, sgACC-hippocampal rsFC was decreased by ketamine compared to placebo; such changes may be relevant to autobiographical recall, rumination [<xref ref-type="bibr" rid="CR42">42</xref>], and the regulation of downstream structures important in emotion, such as the amygdala [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
              <p id="Par46">Notably, sgACC-ventral striatal connectivity was significantly altered by ketamine. sgACC-ventral striatal rsFC changes correlated with improvements in TEPS-anticipatory scores but not TEPS-consummatory scores, suggesting differential involvement of these prefrontal-striatal circuits in temporally distinct aspects of anhedonia. This finding back-translates to preclinical primate work: connectivity between sgACC and ventral regions of the striatum has been causally implicated in ketamine’s ability to ameliorate anticipatory (but not consummatory) reward processing deficits in marmoset models [<xref ref-type="bibr" rid="CR18">18</xref>]. This finding also highlights the importance of distinguishing between different subtypes of anhedonic symptoms; for example, the SHAPS scale does not distinguish between anticipatory <italic>vs.</italic> consummatory anhedonia, and so may be insensitive to changes in specific symptom clusters.</p>
              <p id="Par47">When we carried out whole-brain regressions exploring sgACC rsFC changes associated with ketamine’s anti-anhedonic effects, we identified a cluster in the dACC where connectivity was positively associated with lower anhedonia as measured by SHAPS scores. The dACC is known to be interconnected with sgACC [<xref ref-type="bibr" rid="CR22">22</xref>] and changes in dACC activity have previously been associated with ketamine’s anti-anhedonic effects in both preclinical marmoset models [<xref ref-type="bibr" rid="CR17">17</xref>] and in humans [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Increased connectivity between sgACC and dACC may reflect increased connectivity of sgACC to nodes of the salience network, important in reward processing by identifying salient reward-predicting stimuli [<xref ref-type="bibr" rid="CR44">44</xref>]. In sum, these data suggest that sgACC connectivity to a network including other ACC subregions and the ventral striatum may be modulated by ketamine to improve anhedonia. It is important to note, however, that from fMRI data alone, we cannot be sure if these correlations reflect causal relationships, nor can we establish whether rsFC changes reflect changes in excitatory <italic>vs.</italic> inhibitory connections between these regions.</p>
              <p id="Par48">Limitations of this study include, firstly, the small sample size (particularly when exploring correlations between changes in rsFC and anhedonia scores) which may limit the power to detect changes in ACC rsFC and associations with improvements in symptoms. The within-subject crossover design mitigates this issue to a degree, but replication of these findings in trials with larger sample sizes is critical. Second, the sample size was too small to perform cross-validation using a leave-one-out framework, which would otherwise handle potential bias from the inferential tests being performed on clusters taken from the analysis. Third, the fixed time point analyzed in this study (two days), means we could not ascertain how changes in rsFC develop over the duration of ketamine’s antidepressant effects. Finally, whilst the integrity of the blind for score raters was assessed as reported in a prior manuscript [<xref ref-type="bibr" rid="CR27">27</xref>], the integrity of the blind for participants was not assessed; unblinding effects may confound the improvements in clinical scores following ketamine.</p>
            </sec>
            <sec id="Sec14" sec-type="conclusion">
              <title>Conclusion</title>
              <p id="Par49">We show that different subregions of the ACC are differentially modulated by ketamine, compared to placebo, in TRD <italic>vs.</italic> HV. rsFC between the ACC, insula, and anterior vmPFC is modulated by ketamine compared to placebo, and changes in pgACC-right insula connectivity correlate with improvements in MADRS scores. Post-hoc comparisons within the TRD group illustrate that sgACC undergoes the most substantial modulations, with changes in sgACC-pgACC, sgACC-ventral striatal, and sgACC-dACC connectivity correlating with anhedonia scores. These data provide preliminary evidence suggesting ketamine’s modulation of ACC subregional rsFC is important in mediating its antidepressant and anti-anhedonic effects, and illustrate the importance of ACC segmentation in understanding ketamine’s effects.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <sec id="Sec15">
                <title>Supplementary information</title>
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41398_2023_2674_MOESM1_ESM.docx">
                      <caption>
                        <p>Supplemental</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s41398-023-02674-1.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>The research was carried out at the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). Funding for this work was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH) (ZIAMH002857; NCT00088699; 04-M-0222); a NIHR Academic Clinical Fellowship award (ACF-2022-17-016) to LA; a NARSAD Independent Investigator to CAZ; and a Brain &amp; Behavior Mood Disorders Research Award to CAZ. MAM is employed by King’s College London and his grant funding for the past 3 years is Takeda, Johnson &amp; Johnson, Lundbeck, Wellcome Trust (212952/Z/18/Z; 200102/Z/15/Z), MRC (MR/R005931/1; MR/R005885/1; MR/S003444/1), NIHR (CRF-2016-10023). For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author Manuscript version arising from this submission.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>All authors contributed to the conceptualization of the study. JWE curated the data. LA, PCTH, and JWE analyzed the data. LA visualized the findings and wrote the manuscript. All authors reviewed, edited, and approved the manuscript. MAM and CAZ provided oversight and supervision.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Data are available on request from the corresponding author.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Code availability</title>
              <p>Code is available on request from the corresponding author.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par50">CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2 R,6 R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2 R,6 R)-hydroxynorketamine and (2 S,6 S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lally</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Luckenbaugh</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Ameli</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Roiser</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2014</year>
                  <volume>4</volume>
                  <fpage>e469</fpage>
                  <pub-id pub-id-type="doi">10.1038/tp.2014.105</pub-id>
                  <?supplied-pmid 25313512?>
                  <pub-id pub-id-type="pmid">25313512</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lally</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Luckenbaugh</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Niciu</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Roiser</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Neural correlates of change in major depressive disorder anhedonia following open-label ketamine</article-title>
                  <source>J Psychopharmacol</source>
                  <year>2015</year>
                  <volume>29</volume>
                  <fpage>596</fpage>
                  <lpage>607</lpage>
                  <pub-id pub-id-type="doi">10.1177/0269881114568041</pub-id>
                  <?supplied-pmid 25691504?>
                  <pub-id pub-id-type="pmid">25691504</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wilkowska</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wiglusz</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Gałuszko-Wegielnik</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Włodarczyk</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Cubała</surname>
                      <given-names>WJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression</article-title>
                  <source>Front Psychiatry</source>
                  <year>2021</year>
                  <volume>12</volume>
                  <fpage>704330</fpage>
                  <pub-id pub-id-type="doi">10.3389/fpsyt.2021.704330</pub-id>
                  <?supplied-pmid 34733182?>
                  <pub-id pub-id-type="pmid">34733182</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alexander</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jelen</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>AH</given-names>
                    </name>
                  </person-group>
                  <article-title>The anterior cingulate cortex as a key locus of ketamine’s antidepressant action</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2021</year>
                  <volume>127</volume>
                  <fpage>531</fpage>
                  <lpage>54</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.05.003</pub-id>
                  <?supplied-pmid 33984391?>
                  <pub-id pub-id-type="pmid">33984391</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <mixed-citation publication-type="other">Vogt BA. Mapping Cingulate Subregions. In: <italic>Brain Mapping: An Encyclopaedic Reference</italic>. Academic Press, 2015, pp 325-39.</mixed-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Margulies</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>AMC</given-names>
                    </name>
                    <name>
                      <surname>Uddin</surname>
                      <given-names>LQ</given-names>
                    </name>
                    <name>
                      <surname>Biswal</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>Castellanos</surname>
                      <given-names>FX</given-names>
                    </name>
                    <name>
                      <surname>Milham</surname>
                      <given-names>MP</given-names>
                    </name>
                  </person-group>
                  <article-title>Mapping the functional connectivity of anterior cingulate cortex</article-title>
                  <source>Neuroimage</source>
                  <year>2007</year>
                  <volume>37</volume>
                  <fpage>579</fpage>
                  <lpage>88</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.05.019</pub-id>
                  <?supplied-pmid 17604651?>
                  <pub-id pub-id-type="pmid">17604651</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fuchikami</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wohleb</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Land</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>DiLeone</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions</article-title>
                  <source>Proc Natl Acad Sci USA</source>
                  <year>2015</year>
                  <volume>112</volume>
                  <fpage>8106</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1414728112</pub-id>
                  <?supplied-pmid 26056286?>
                  <pub-id pub-id-type="pmid">26056286</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gasull-Camós</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tarrés-Gatius</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Artigas</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Castañé</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2017</year>
                  <volume>7</volume>
                  <fpage>e1038</fpage>
                  <pub-id pub-id-type="doi">10.1038/tp.2017.7</pub-id>
                  <?supplied-pmid 28221365?>
                  <pub-id pub-id-type="pmid">28221365</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shirayama</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Hashimoto</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression</article-title>
                  <source>Eur Arch Psychiatry Clin Neurosci</source>
                  <year>2017</year>
                  <volume>267</volume>
                  <fpage>177</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00406-016-0718-1</pub-id>
                  <?supplied-pmid 27480092?>
                  <pub-id pub-id-type="pmid">27480092</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dolzani</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Baratta</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>Moss</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Leslie</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>Tilden</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Sørensen</surname>
                      <given-names>AT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Inhibition of a descending prefrontal circuit prevents ketamine-induced stress resilience in females</article-title>
                  <source>eNeuro</source>
                  <year>2018</year>
                  <volume>5</volume>
                  <fpage>ENEURO.0025</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="doi">10.1523/ENEURO.0025-18.2018</pub-id>
                  <?supplied-pmid 29516036?>
                  <pub-id pub-id-type="pmid">29516036</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>R-J</given-names>
                    </name>
                    <name>
                      <surname>Dwyer</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Banasr</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Son</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2011</year>
                  <volume>69</volume>
                  <fpage>754</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.12.015</pub-id>
                  <?supplied-pmid 21292242?>
                  <pub-id pub-id-type="pmid">21292242</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Shirayama</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J-C</given-names>
                    </name>
                    <name>
                      <surname>Ren</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Yao</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2015</year>
                  <volume>5</volume>
                  <fpage>e632</fpage>
                  <pub-id pub-id-type="doi">10.1038/tp.2015.136</pub-id>
                  <?supplied-pmid 26327690?>
                  <pub-id pub-id-type="pmid">26327690</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Downey</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Dutta</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>McKie</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dawson</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Dourish</surname>
                      <given-names>CT</given-names>
                    </name>
                    <name>
                      <surname>Craig</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate</article-title>
                  <source>Eur Neuropsychopharmacol</source>
                  <year>2016</year>
                  <volume>26</volume>
                  <fpage>994</fpage>
                  <lpage>1003</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.03.006</pub-id>
                  <?supplied-pmid 27133029?>
                  <pub-id pub-id-type="pmid">27133029</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McMillan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sumner</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Forsyth</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Malpas</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Maxwell</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder</article-title>
                  <source>Prog Neuro-Psychopharmacol Biol Psychiatry</source>
                  <year>2020</year>
                  <volume>99</volume>
                  <fpage>109838</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.pnpbp.2019.109838</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Fields</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>DeWilde</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2015</year>
                  <volume>5</volume>
                  <fpage>e509</fpage>
                  <pub-id pub-id-type="doi">10.1038/tp.2015.10</pub-id>
                  <?supplied-pmid 25689570?>
                  <pub-id pub-id-type="pmid">25689570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Akil</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hen</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Javitch</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>McEwen</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Treatment resistant depression: a multi-scale, systems biology approach</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2018</year>
                  <volume>84</volume>
                  <fpage>272</fpage>
                  <lpage>88</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.08.019</pub-id>
                  <?supplied-pmid 28859997?>
                  <pub-id pub-id-type="pmid">28859997</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alexander</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Gaskin</surname>
                      <given-names>PLR</given-names>
                    </name>
                    <name>
                      <surname>Sawiak</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Fryer</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>YT</given-names>
                    </name>
                    <name>
                      <surname>Cockcroft</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Fractionating blunted reward processing characteristic of anhedonia by over-activating primate subgenual anterior cingulate cortex</article-title>
                  <source>Neuron</source>
                  <year>2019</year>
                  <volume>101</volume>
                  <fpage>307</fpage>
                  <lpage>20.e6</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuron.2018.11.021</pub-id>
                  <?supplied-pmid 30528065?>
                  <pub-id pub-id-type="pmid">30528065</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wood</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Alexander</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Alsiö</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Santangelo</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>McIver</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Cockcroft</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Chemogenetics identifies separate area 25 brain circuits involved in anhedonia and anxiety in marmosets</article-title>
                  <source>Sci Transl Med</source>
                  <year>2023</year>
                  <volume>15</volume>
                  <fpage>eade1779</fpage>
                  <pub-id pub-id-type="doi">10.1126/scitranslmed.ade1779</pub-id>
                  <?supplied-pmid 37018416?>
                  <pub-id pub-id-type="pmid">37018416</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mkrtchian</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Kraus</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Yuan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kadriu</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2020</year>
                  <volume>26</volume>
                  <fpage>1</fpage>
                  <lpage>10</lpage>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morris</surname>
                      <given-names>LS</given-names>
                    </name>
                    <name>
                      <surname>Costi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stern</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine normalizes subgenual cingulate cortex hyper-activity in depression</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2020</year>
                  <volume>45</volume>
                  <fpage>975</fpage>
                  <lpage>81</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41386-019-0591-5</pub-id>
                  <?supplied-pmid 31896116?>
                  <pub-id pub-id-type="pmid">31896116</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arnsten</surname>
                      <given-names>AFT</given-names>
                    </name>
                    <name>
                      <surname>Joyce</surname>
                      <given-names>MKP</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>AC</given-names>
                    </name>
                  </person-group>
                  <article-title>The Aversive Lens: stress effects on the prefrontal-cingulate cortical pathways that regulate emotion</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2023</year>
                  <volume>145</volume>
                  <fpage>105000</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.neubiorev.2022.105000</pub-id>
                  <?supplied-pmid 36529312?>
                  <pub-id pub-id-type="pmid">36529312</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joyce</surname>
                      <given-names>MKP</given-names>
                    </name>
                    <name>
                      <surname>García-Cabezas</surname>
                      <given-names>MÁ</given-names>
                    </name>
                    <name>
                      <surname>John</surname>
                      <given-names>YJ</given-names>
                    </name>
                    <name>
                      <surname>Barbas</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Serial prefrontal pathways are positioned to balance cognition and emotion in primates</article-title>
                  <source>J Neurosci</source>
                  <year>2020</year>
                  <volume>40</volume>
                  <fpage>8306</fpage>
                  <lpage>28</lpage>
                  <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0860-20.2020</pub-id>
                  <?supplied-pmid 32989097?>
                  <pub-id pub-id-type="pmid">32989097</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ansell</surname>
                      <given-names>EB</given-names>
                    </name>
                    <name>
                      <surname>Rando</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tuit</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Guarnaccia</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sinha</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Cumulative adversity and smaller gray matter volume in medial prefrontal, anterior cingulate, and insula regions</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2012</year>
                  <volume>72</volume>
                  <fpage>57</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2011.11.022</pub-id>
                  <?supplied-pmid 22218286?>
                  <pub-id pub-id-type="pmid">22218286</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arnsten</surname>
                      <given-names>AFT</given-names>
                    </name>
                    <name>
                      <surname>Datta</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The genie in the bottle-magnified calcium signaling in dorsolateral prefrontal cortex</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2021</year>
                  <volume>26</volume>
                  <fpage>3684</fpage>
                  <lpage>700</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41380-020-00973-3</pub-id>
                  <?supplied-pmid 33319854?>
                  <pub-id pub-id-type="pmid">33319854</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cash</surname>
                      <given-names>RFH</given-names>
                    </name>
                    <name>
                      <surname>Weigand</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zalesky</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Siddiqi</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Downar</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>PB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Using brain imaging to improve spatial targeting of transcranial magnetic stimulation for depression</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2021</year>
                  <volume>90</volume>
                  <fpage>689</fpage>
                  <lpage>700</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2020.05.033</pub-id>
                  <?supplied-pmid 32800379?>
                  <pub-id pub-id-type="pmid">32800379</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Evans</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Szczepanik</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Brutsché</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2018</year>
                  <volume>84</volume>
                  <fpage>582</fpage>
                  <lpage>90</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2018.01.027</pub-id>
                  <?supplied-pmid 29580569?>
                  <pub-id pub-id-type="pmid">29580569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Ballard</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Gould</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Moaddel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Brutsche</surname>
                      <given-names>NE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2019</year>
                  <volume>24</volume>
                  <fpage>1040</fpage>
                  <lpage>52</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41380-018-0028-2</pub-id>
                  <?supplied-pmid 29487402?>
                  <pub-id pub-id-type="pmid">29487402</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Asberg</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>A new depression scale designed to be sensitive to change</article-title>
                  <source>Br J Psychiatry</source>
                  <year>1979</year>
                  <volume>134</volume>
                  <fpage>382</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id>
                  <?supplied-pmid 444788?>
                  <pub-id pub-id-type="pmid">444788</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Snaith</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Morley</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Humayan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hargreaves</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Trigwell</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale</article-title>
                  <source>Br J Psychiatry</source>
                  <year>1995</year>
                  <volume>167</volume>
                  <fpage>99</fpage>
                  <lpage>103</lpage>
                  <pub-id pub-id-type="doi">10.1192/bjp.167.1.99</pub-id>
                  <?supplied-pmid 7551619?>
                  <pub-id pub-id-type="pmid">7551619</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gard</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Gard</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Kring</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>John</surname>
                      <given-names>OP</given-names>
                    </name>
                  </person-group>
                  <article-title>Anticipatory and consummatory components of the experience of pleasure: a scale development study</article-title>
                  <source>J Res Personal</source>
                  <year>2006</year>
                  <volume>40</volume>
                  <fpage>1086</fpage>
                  <lpage>102</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jrp.2005.11.001</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kühn</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vanderhasselt</surname>
                      <given-names>M-A</given-names>
                    </name>
                    <name>
                      <surname>De Raedt</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Gallinat</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Why ruminators won’t stop: the structural and resting state correlates of rumination and its relation to depression</article-title>
                  <source>J Affect Disord</source>
                  <year>2012</year>
                  <volume>141</volume>
                  <fpage>352</fpage>
                  <lpage>60</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jad.2012.03.024</pub-id>
                  <?supplied-pmid 22497878?>
                  <pub-id pub-id-type="pmid">22497878</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cox</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>AFNI: software for analysis and visualization of functional magnetic resonance neuroimages</article-title>
                  <source>Comput Biomed Res</source>
                  <year>1996</year>
                  <volume>29</volume>
                  <fpage>162</fpage>
                  <lpage>73</lpage>
                  <pub-id pub-id-type="doi">10.1006/cbmr.1996.0014</pub-id>
                  <?supplied-pmid 8812068?>
                  <pub-id pub-id-type="pmid">8812068</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>ZS</given-names>
                    </name>
                  </person-group>
                  <article-title>FATCAT: (an efficient) functional and tractographic connectivity analysis toolbox</article-title>
                  <source>Brain Connect</source>
                  <year>2013</year>
                  <volume>3</volume>
                  <fpage>523</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1089/brain.2013.0154</pub-id>
                  <?supplied-pmid 23980912?>
                  <pub-id pub-id-type="pmid">23980912</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>ZS</given-names>
                    </name>
                    <name>
                      <surname>Britton</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Pine</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>Linear mixed-effects modeling approach to FMRI group analysis</article-title>
                  <source>Neuroimage</source>
                  <year>2013</year>
                  <volume>73</volume>
                  <fpage>176</fpage>
                  <lpage>90</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.01.047</pub-id>
                  <?supplied-pmid 23376789?>
                  <pub-id pub-id-type="pmid">23376789</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kriegeskorte</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Simmons</surname>
                      <given-names>WK</given-names>
                    </name>
                    <name>
                      <surname>Bellgowan</surname>
                      <given-names>PSF</given-names>
                    </name>
                    <name>
                      <surname>Baker</surname>
                      <given-names>CI</given-names>
                    </name>
                  </person-group>
                  <article-title>Circular analysis in systems neuroscience: the dangers of double dipping</article-title>
                  <source>Nat Neurosci</source>
                  <year>2009</year>
                  <volume>12</volume>
                  <fpage>535</fpage>
                  <lpage>40</lpage>
                  <pub-id pub-id-type="doi">10.1038/nn.2303</pub-id>
                  <?supplied-pmid 19396166?>
                  <pub-id pub-id-type="pmid">19396166</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joyce</surname>
                      <given-names>MKP</given-names>
                    </name>
                    <name>
                      <surname>Barbas</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Cortical connections position primate area 25 as a keystone for interoception, emotion, and memory</article-title>
                  <source>J Neurosci</source>
                  <year>2018</year>
                  <volume>38</volume>
                  <fpage>1677</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2363-17.2017</pub-id>
                  <?supplied-pmid 29358365?>
                  <pub-id pub-id-type="pmid">29358365</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drevets</surname>
                      <given-names>WC</given-names>
                    </name>
                    <name>
                      <surname>Savitz</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Trimble</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The subgenual anterior cingulate cortex in mood disorders</article-title>
                  <source>CNS Spectr</source>
                  <year>2008</year>
                  <volume>13</volume>
                  <fpage>663</fpage>
                  <lpage>81</lpage>
                  <pub-id pub-id-type="doi">10.1017/S1092852900013754</pub-id>
                  <?supplied-pmid 18704022?>
                  <pub-id pub-id-type="pmid">18704022</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sapolsky</surname>
                      <given-names>RM</given-names>
                    </name>
                  </person-group>
                  <article-title>Depression, antidepressants, and the shrinking hippocampus</article-title>
                  <source>Proc Natl Acad Sci USA</source>
                  <year>2001</year>
                  <volume>98</volume>
                  <fpage>12320</fpage>
                  <lpage>2</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.231475998</pub-id>
                  <?supplied-pmid 11675480?>
                  <pub-id pub-id-type="pmid">11675480</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carreno</surname>
                      <given-names>FR</given-names>
                    </name>
                    <name>
                      <surname>Donegan</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Boley</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>DeGuzman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Frazer</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2016</year>
                  <volume>21</volume>
                  <fpage>1298</fpage>
                  <lpage>308</lpage>
                  <pub-id pub-id-type="doi">10.1038/mp.2015.176</pub-id>
                  <?supplied-pmid 26619811?>
                  <pub-id pub-id-type="pmid">26619811</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegel</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Palanca</surname>
                      <given-names>BJA</given-names>
                    </name>
                    <name>
                      <surname>Ances</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Kharasch</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Schweiger</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Yingling</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression</article-title>
                  <source>Psychopharmacology</source>
                  <year>2021</year>
                  <volume>238</volume>
                  <fpage>1157</fpage>
                  <lpage>69</lpage>
                  <?supplied-pmid 33483802?>
                  <pub-id pub-id-type="pmid">33483802</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wong</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>O’Daly</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Stone</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?</article-title>
                  <source>PeerJ</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <fpage>e1710</fpage>
                  <pub-id pub-id-type="doi">10.7717/peerj.1710</pub-id>
                  <?supplied-pmid 26925332?>
                  <pub-id pub-id-type="pmid">26925332</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Disner</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Beevers</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Haigh</surname>
                      <given-names>EAP</given-names>
                    </name>
                    <name>
                      <surname>Beck</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>Neural mechanisms of the cognitive model of depression</article-title>
                  <source>Nat Rev Neurosci</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <fpage>467</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrn3027</pub-id>
                  <?supplied-pmid 21731066?>
                  <pub-id pub-id-type="pmid">21731066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duvarci</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pare</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Amygdala microcircuits controlling learned fear</article-title>
                  <source>Neuron</source>
                  <year>2014</year>
                  <volume>82</volume>
                  <fpage>966</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuron.2014.04.042</pub-id>
                  <?supplied-pmid 24908482?>
                  <pub-id pub-id-type="pmid">24908482</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pisoni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Smoski</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Neural signatures of saliency-mapping in anhedonia: A narrative review</article-title>
                  <source>Psychiatry Res</source>
                  <year>2021</year>
                  <volume>304</volume>
                  <fpage>114123</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.psychres.2021.114123</pub-id>
                  <?supplied-pmid 34333324?>
                  <pub-id pub-id-type="pmid">34333324</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
